Future clinical and research strategies must prioritize behavioral innovations to improve adherence, explore the synergistic effects of exercise with novel pharmacological treatments like GLP-1 receptor agonists, and foster sustainable, active lifestyles for patients with type 2 diabetes. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.